Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
AbstractPsoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with patients frequently suffering from reduced quality of life, psychologic distress and debilitating comorbidities. Biologic agents are used to establish and maintain disease control in patients with moderate-to-severe psoriasis and are essential to improving quality of life. However, a substantial proportion of patients have limited access to therapy due to economics, health policies and clinical considerations, which creates clinical unmet ne...
Source: Dermatology and Therapy - September 14, 2023 Category: Dermatology Source Type: research
Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children
AbstractPityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women of all ages, including children. PRP is characterized by follicular and palmoplantar hyperkeratosis and salmon-colored scaling plaques. The exact pathogenesis of PRP is still unknown; most PRP cases are acquired, but some cases may show a familial occurrence, often associated with a mutation in the CARD14 gene. Due to the rarity of PRP, treatment recommendations are based mainly on case reports, small case series and expert opinions and still represent a major therapeutic challenge, especially in children. A growing number...
Source: Dermatology and Therapy - September 13, 2023 Category: Dermatology Source Type: research
Varicella Zoster Virus-Specific Hyperimmunoglobulin in the Adjuvant Treatment of Immunocompromised Herpes Zoster Patients: A Case Series
ConclusionThis case series demonstrates highly satisfactory treatment effectiveness and tolerability for VZV-IgG in the adjuvant treatment of immunocompromised HZ patients and supports early intensification of HZ therapy in patients at high risk of severe disease progression. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 13, 2023 Category: Dermatology Source Type: research
Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children
AbstractPityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women of all ages, including children. PRP is characterized by follicular and palmoplantar hyperkeratosis and salmon-colored scaling plaques. The exact pathogenesis of PRP is still unknown; most PRP cases are acquired, but some cases may show a familial occurrence, often associated with a mutation in the CARD14 gene. Due to the rarity of PRP, treatment recommendations are based mainly on case reports, small case series and expert opinions and still represent a major therapeutic challenge, especially in children. A growing number...
Source: Dermatology and Therapy - September 13, 2023 Category: Dermatology Source Type: research
Varicella Zoster Virus-Specific Hyperimmunoglobulin in the Adjuvant Treatment of Immunocompromised Herpes Zoster Patients: A Case Series
ConclusionThis case series demonstrates highly satisfactory treatment effectiveness and tolerability for VZV-IgG in the adjuvant treatment of immunocompromised HZ patients and supports early intensification of HZ therapy in patients at high risk of severe disease progression. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 13, 2023 Category: Dermatology Source Type: research
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials
AbstractTapinarof cream 1% (VTAMA®; Dermavant Sciences, Inc.) is a non-steroidal, topical, aryl hydrocarbon receptor agonist approved by the US Food and Drug Administration (FDA) to treat plaque psoriasis in adults and under investigation for the treatment of psoriasis in children down to 2 years of age, and for atopic dermatitis in adults and children down to 2 years of age. The PSOARING phase 3 clinical trial program evaluated tapinarof cream 1% once daily (QD) in adults with mild to severe plaque psoriasis for up to 52 weeks (NCT03956355, NCT03983980, NCT04053387). Here we pres ent case photography documenting out...
Source: Dermatology and Therapy - September 11, 2023 Category: Dermatology Source Type: research
Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
We present a case of a 28-year-old female patient with acute onset of guttate psoriasis after a blistering sunburn. She had no personal or family history of psoriasis or chronic inflammatory skin disease. The guttate psoriasis was refractory to topical treatment. After the first dose of guselkumab (100 mg subcutaneous injection), the patient experienced near-clearance of her guttate psoriasis, with continued improvement and drug-free remission 8 months after cessation of treatment. Dermatologists could consider guselkumab as a treatment option for patients with guttate psoriasis. Future studies should examine the potent...
Source: Dermatology and Therapy - September 7, 2023 Category: Dermatology Source Type: research
Dermoscopy as a Noninvasive Diagnostic Tool for Hailey-Hailey Disease and Darier Disease
ConclusionDermoscopy reveals distinctive features of HHD and DD, respectively. Therefore, we conclude that dermoscopy can be an excellent complementary noninvasive tool in the diagnostic process of patients with HHD and DD. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 5, 2023 Category: Dermatology Source Type: research
Comorbidity Burden Among Patients with Vitiligo in the United States: A Large-Scale Retrospective Claims Database Analysis
ConclusionResults of this retrospective analysis demonstrated that patients were much more likely to be diagnosed with autoimmune or psychiatric comorbidities following a vitiligo diagnosis, which likely contributed to increased economic burden and lower quality of life. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 5, 2023 Category: Dermatology Source Type: research
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-R α Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
ConclusionsAK120 exhibited an acceptable safety profile in healthy and AD subjects, and showed preliminary efficacy. These findings support the continued investigation of AK120 for treating AD.Clinical Trial RegistrationClinicalTrials.gov identification number: NCT04256174. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 5, 2023 Category: Dermatology Source Type: research
Dermoscopy as a Noninvasive Diagnostic Tool for Hailey-Hailey Disease and Darier Disease
ConclusionDermoscopy reveals distinctive features of HHD and DD, respectively. Therefore, we conclude that dermoscopy can be an excellent complementary noninvasive tool in the diagnostic process of patients with HHD and DD. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 5, 2023 Category: Dermatology Source Type: research
Comorbidity Burden Among Patients with Vitiligo in the United States: A Large-Scale Retrospective Claims Database Analysis
ConclusionResults of this retrospective analysis demonstrated that patients were much more likely to be diagnosed with autoimmune or psychiatric comorbidities following a vitiligo diagnosis, which likely contributed to increased economic burden and lower quality of life. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 5, 2023 Category: Dermatology Source Type: research
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-R α Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
ConclusionsAK120 exhibited an acceptable safety profile in healthy and AD subjects, and showed preliminary efficacy. These findings support the continued investigation of AK120 for treating AD.Clinical Trial RegistrationClinicalTrials.gov identification number: NCT04256174. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 5, 2023 Category: Dermatology Source Type: research
